Introduction
============

Nontuberculous mycobacteria (NTM) are a large, diverse group of environment organisms that are ubiquitous in the soil, water, animals, human, and food ([@B10]; [@B21]). Despite of low pathogenicity to humans, NTM can cause a wide array of clinical illness, especially in human immune-deficiency virus (HIV) infected patients or those with severely compromised immune systems ([@B21]). In recent years, increasing attention has been paid to disease caused by NTM because of its more prevalent incidence globally ([@B14]; [@B24]).

Only behind *Mycobacterium avium* complex, *Mycobacterium kansasii* is the second most common cause of NTM diseases in South American and some European countries ([@B14]). In addition to the most frequent pulmonary disease, *M. kansasii* is a contributor to various clinical manifestations, including extrapulmonary and disseminated diseases in patients with immunodeficiencies ([@B5]; [@B20]). Previous epidemiological studies have demonstrated that patients with chronic lung disease, previous mycobacterial disease, malignancy, and alcoholism are at high risk for *M. kansasii* infection ([@B11]). *M. kansasii* is often recovered from tap water, and occasionally from natural water ([@B18]; [@B26]; [@B27]). Due to wide exposure to the bacterium, human-to-human transmission of *M. kansasii* is traditionally thought to be uncommon ([@B23]). However, a recent report from [@B23] observed the potential transmission of *M. kansasii* given the ideal circumstances, providing important insights for public health concern regarding *M. kansasii*.

PCR-restriction fragment analysis of the *hsp65* gene (PRA) is a powerful technique of differentiating heterogeneous subtypes of *M. kansasii* ([@B28]; [@B25]). To date, seven subtypes (I-VII) have been identified based on the PCR-RFLP profiles ([@B19]; [@B22]; [@B25]). Of these seven subtypes, subtype I represents the most frequent isolates contributing to human disease ([@B27]), and subtype II is likely to be observed in HIV-infected patients, indicating that it may act as an opportunistic agent ([@B32]). In contrast, the other five subtypes are generally isolated from environmental samples rather than human specimens ([@B1]). The niche heterogeneity indicates that there may be diverse pathogenicity and biological features among the *M. kansasii* subtypes ([@B25]). Considering drug susceptibility is an important indicator for predicting the clinical outcome of patients infected with *M. kansasii*, it is meaningful to investigate the assumed difference in drug susceptibility profiles of these seven subtypes. Unfortunately, limited data is known regarding this issue. The aim of the present study was to analyze *M. kansasii* subtypes isolated from patients in China, and to explore the antimicrobial susceptibility of the differentiation among these diverse subtypes.

Materials and Methods {#s1}
=====================

Ethics Statement
----------------

The protocols applied in this study were approved by the Ethics Committee of Beijing Hospital. The *M. kansasii* isolates obtained from patients were anonymized, processed using strain number only and were not associated with any identifying details.

*M. kansasii* Isolates
----------------------

The strains used in this study were collected from national surveillance of drug resistant tuberculosis from 2008 to 2015 (Zhao et al., 2012; Zhang et al., 2015). All the positive mycobacterial cultures were transferred to National Tuberculosis Reference Laboratory for species identification. Conventional species identification was performed with the Löwenstein--Jensen (L--J) medium containing paranitrobenzoic acid (PNB) and thiophen-2-carboxylic acid hydrazide (TCH) ([@B34]). The isolates identified as NTM by biochemical method were further divided into species level with sequencing of multiple genes, including 16S rRNA, 65-kD heat shock protein (*hsp65*), RNA polymerase subunit beta (*rpoB*), and 16S-23S rRNA internal transcribed spacer (ITS) sequence ([@B34]). Briefly, the crude genomic DNA was extracted from colonies harvested from L--J medium according to previous report. The 50 μl amplification mixtures were prepared as follow: 25 μl 2× GoldStar MasterMix (CWBio, Beijing, China), 0.2 μM of each primer set and 5 μl of genomic DNA. PCR program was performed for 35 cycles (94°C for 60 s, 60°C for 60 s, and 72°C for 60 s). The amplicons were sent to Tsingke Company (Beijing, China) for sequencing service. DNA sequence analysis was performed by alignment with the homologous sequences of the reference mycobacterial strains using multiple sequence alignments^[1](#fn01){ref-type="fn"}^. A total of 78 *M. kansasii* isolates confirmed by molecular method were enrolled for further drug susceptibility testing and PRA identification.

Minimal Inhibitory Concentration (MIC)
--------------------------------------

Antimicrobial susceptibility testing was performed following the guidelines by the [@B7]. Cation-adjusted Mueller-Hinton broth (CAMHB) plus 5% OADC (oleic acid- albumin-dextrose-catalase) was used for broth microdilution testing. A total of twenty antimicrobial agents were selected for MIC determination, including isoniazid (INH), streptomycin (STR), clarithromycin (CLA), amikacin (AMK), rifampicin (RIF), rifabutin (RFB), ethambutol (EMB), linezolid (LZD), moxifloxacin (MOX), levofloxacin (LFX), gatifloxacin (GAT), sulfamethoxazole (SUL), azithromycin (AZM), capreomycin (CAP), tigecycline (TGC), meropenem (MER), minocyline (MIN), cefoxitin (CFX), tobramycin (TOB) and clofazimine (CLO). The concentrations tested ranged from 0.0625 to 128 μg/ml. The breakpoints of antimicrobial agents were recommended by the CLSI:CLA, \> 16 μg/ml;RFB, \> 1 μg/ml;AMK, \> 32 μg/ml;EMB, \> 4 μg/ml;LZD, \> 16 μg/ml; MOX, \> 2 μg/mL;RFB, \> 2 μg/ml; and SUL, \> 32 μg/ml ([@B7]). In addition, the breakpoint of levofloxacin was referenced from a previous report, defined as \>2 μg/ml ([@B15]). For gatifloxacin, the temporary breakpoint was set as \> 2 μg/ml, which was also used as breakpoint values of ciprofloxacin, levofloxacin and moxifloxacin. The reference *M. kansasii* strain (ATCC12478) was enrolled in each batch for quality control purpose.

PRA Identification
------------------

The PRA identification was performed as previously described ([@B28]). The 441-bp fragment of the *hsp65* gene was amplified from genomic DNA with primers Tb11 and Tb12. The PCR product was subjected to restriction enzyme analysis with *Bst*E II and *Hae* III. The restriction fragments were identified by electrophoresis on a 3% of agarose gel. The patterns of PRA were evaluated at the SwissPRAsite^[2](#fn02){ref-type="fn"}^.

DNA Sequencing
--------------

The region corresponding to domain V of the 23S ribosomal RNA (23S rRNA) gene was amplified with primer F1 (5′-GCAAGGGTGAAGCGGAGAA-3′) and primer R1 (5′-GCACTTACACTCGCCACCTGA-3′). The amplicons were analyzed by DNA sequencing. The DNA sequences were aligned with the homologous sequences of the reference *M. kansasii* strain (ATCC12478) with multiple sequence alignments^[3](#fn03){ref-type="fn"}^.

Statistical Analysis
--------------------

The differences in proportions of drug resistance between different *M. kansasii* subtypes were evaluated with chi-square test or Fisher's exact test. Statistical analysis was performed using SPSS, version 15.0 (SPSS Inc., Chicago, IL, USA). The difference was considered to be statistically significant when *P* \< 0.05.

Results
=======

Drug Susceptibility Testing
---------------------------

A total of 78 *M. kansasii* strains from 13 provinces of China were enrolled for further drug susceptibility testing in this study (**Figure [1](#F1){ref-type="fig"}**). The range of MICs of each antimicrobial agent for *M. kansasii* isolates is detailed qualitatively in **Table [1](#T1){ref-type="table"}**. AMK was the most highly active against *M. kansasii* strains, and only 4 isolates (5.1%) exhibited *in vitro* resistance to AMK. Fluoroquinolone susceptibility was variable among MOX, LFX and GAT, the MIC~50~s and MIC~90~s of which were 0.25 μg/ml and 4 μg/ml for MOX, 2 μg/ml and 16 μg/ml for LFX, and 0.5 μg/ml and 4 μg/ml for GAT, respectively. When using the CLSI breakpoints, the percentage of LFX-resistant strains among the 78 *M. kansasii* isolates was 39.7% (31/78), which was significantly higher than that of MOX (16.7%, *P* = 0.001) and GAT (19.2%, *P* = 0.005). The levels of cross-resistance among fluoroquinolones are presented in **Figure [2](#F2){ref-type="fig"}**. Of the 31 isolates that were resistant to LFX, 13 (41.9%) and 15 (48.4%) isolates exhibited resistance to MOX and GAT, respectively. In addition, the isolates resistant to MOX and/or GAT were all resistant to LFX. For rifamycins, there were 44 (56.4%) and 27 (34.6%) isolates resistant to RIF and RFB, respectively. Statistical analysis revealed that the percentage of RFB-resistant isolates was significantly lower than that of RIF (*P* = 0.006).
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###### 

*In vitro* susceptibility of *Mycobacterium kansasii* isolates against 20 antimicrobial agents enrolled in this study.

  Antimicrobial agent   MIC range (μg/ml)   MIC~50~ (μg/ml)   MIC~90~ (μg/ml)   No. of resistant strains (%)^a^
  --------------------- ------------------- ----------------- ----------------- ---------------------------------
  CLA                   0.063--128          0.25              128               16 (20.5)
  AMK                   0.5--64             4                 32                4 (5.1)
  RIF                   0.063--128          2                 32                44 (56.4)
  RFB                   0.063--64           0.25              32                27 (34.6)
  EMB                   0.13--64            2                 32                16 (20.5)
  LZD                   0.13--128           4                 128               25 (32.1)
  MOX                   0.063--16           0.25              4                 13 (16.7)
  LFX                   0.063--32           2                 16                31 (39.7)
  GAT                   0.063--16           0.5               4                 15 (19.2)
  SUL                   0.25--128           4                 128               13 (16.7)
  AZM                   0.5--128            16                32                --
  CAP                   0.063--128          1                 32                --
  TGC                   0.25--128           64                128               --
  MER                   0.25--128           128               128               --
  MIN                   0.25--128           4                 32                --
  STR                   1--128              8                 128               --
  CFX                   2--128              128               128               --
  TOB                   0.5--128            8                 64                --
  CLO                   0.06--128           1                 64                --
  INH                   1--64               4                 64                --

a

INH, isoniazid; STR, streptomycin; CLA, clarithromycin; AMK, amikacin; RIF, rifampicin; RFB, rifabutin; EMB, ethambutol; LZD, linezolid; MOX, moxifloxacin; LFX, levofloxacin; GAT, gatifloxacin; SUL, sulfamethoxazole; AZM, azithromycin; CAP, capreomycin; TGC, tigecycline; MER, meropenem; MIN, minocycline; CFX, cefoxitin; TOB, tobramycin; CLO, clofazimine.

b

MIC50 represents the concentration required to inhibit the growth of 50% of the strains; MIC90 represents the concentration required to inhibit the growth of 90% of the strains.
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We further analyzed the drug susceptibility of *M. kansasii* isolates against antimicrobial agents without the breakpoint values. Out of these ten drugs, CAP showed the most activity against *M. kansasii*, with a MIC~50~ of 1 μg/ml and an MIC~90~ of 32 μg/ml. In contrast, TGC, MER and CFX exhibited poor activity against *M. kansasii*, the MIC~50~s and MIC~90~s of which were higher than 64μg/ml.

Distribution of Subtypes
------------------------

All the 78 *M. kansasii* isolates were genotyped by PDA method. As shown in **Table [2](#T2){ref-type="table"}**, they were classified as four different subtypes, including subtype I, II, III, and IV. Of these subtypes, subtype I was the most frequent genotype in China, accounting for 71.8% (56/78) of *M. kansasii* isolates. In addition, there were 11 (14.1%), 8 (10.3%), and 3 (3.8%) isolates belonging to subtype II, III, and IV, respectively.

###### 

Distribution of *M. kansasii* classified as different subtypes.

  Subtype   No. of isolates (%)   PCR-RFLP profiles of *hsp65*   
  --------- --------------------- ------------------------------ --------------
  I         56 (71.8)             240, 210                       140, 105, 80
  II        11 (14.1)             240, 135, 85                   140, 105
  III       8 (10.3)              240, 135, 85                   140, 95, 70
  IV        3 (3.8)               240, 125, 85                   140, 115, 70

Association between Subtypes and Drug Susceptibility
----------------------------------------------------

We further explored the relationship between genetic subtypes and *in vitro* drug susceptibility of *M. kansasii*, which is summarized in **Table [3](#T3){ref-type="table"}**. Overall, resistance to CLA was noted in 26.8% (15/56) of subtype I isolates, while only 4.5% (1/22) of isolates from other subtypes was resistant to CLA. Statistical analysis revealed that the proportion of CLA-resistance among subtype I was significantly higher than that among other subtypes (*P* = 0.031). Similarly, subtype I seemed more resistant to EMB (25.0% vs. 9.1%), MOX (33.9% vs. 9.1%), and GAT (23.2% vs. 9.1%) than other subtypes, while the difference was not significant (*P* \> 0.05), which might be due to the small sample size. In addition, our data revealed that no statistically significant difference between subtype I and other subtypes in the prevalence of RIF-, RFB-, LZD-, and LFX-resistance (*P* \> 0.05).

###### 

Percentage of drug resistance among different subtypes of *M. kansasii* isolates.

  Antimicrobial agent   No. of resistant isolates (%)   *P*-value   
  --------------------- ------------------------------- ----------- -------
  CLA                   15 (26.8)                       1 (4.5)     0.031
  AMK                   4 (7.1)                         0 (0.0)     0.572
  RIF                   31 (55.4)                       13 (59.1)   0.765
  RFB                   19 (33.9)                       8 (36.4)    0.839
  EMB                   14 (25.0)                       2 (9.1)     0.211
  LZD                   19 (25.0)                       6 (27.3)    0.571
  MOX                   11 (33.9)                       2 (9.1)     0.330
  LFX                   24 (42.9)                       7 (31.8)    0.370
  GAT                   13 (23.2)                       2 (9.1)     0.210
  SUL                   11 (19.6)                       2 (9.1)     0.330

Mutations in 23S Ribosomal RNA Conferring CLA Resistance
--------------------------------------------------------

As shown in **Table [4](#T4){ref-type="table"}**, the presence of mutations in 23S rRNA was associated with 56.2% (9/16) of CLA-resistant isolates, while 7 (43.8%) of the 16 CLA-resistant isolates were found to have no mutations at positions 2058 and 2059. A total of two types of mutations were observed in 23S rRNA. The most frequent mutation conferring CLA resistance was A-to-T substitution at position 2058, and six isolates harboring this mutation showed resistant to CLA, the MICs of which ranged from 32 to 128 μg/ml. In addition, another substitution at position 2058 (A-to-C) was found in three CLA-resistant isolates.

###### 

Minimal inhibitory concentration (MICs) of CLA and AZM and mutations in the 23S rRNA gene in CLA-resistant *M. kansasii* isolates.

  Mutation in 23S rRNA   MIC range of CLA (μg/ml)   MIC range of AZM (μg/ml)   No. of isolates (%)
  ---------------------- -------------------------- -------------------------- ---------------------
  A2058T                 32--128                    16--128                    6 (37.5)
  A2058C                 64--128                    32--128                    3 (18.8)
  NA                     32--128                    4--128                     7 (43.8)
  Total                  32--128                    4--128                     16 (100.0)

Discussion
==========

To our best knowledge, the present study is the first provided fundamental information on the drug susceptibility and molecular analysis of *M. kansasii* isolates from China. In keeping with previous reports, our results demonstrated that AMK exhibits favorable *in vitro* activity against *M. kansasii* isolates, which supports its important role in the initial treatment of *M. kansasii* infections ([@B29]; [@B8]). Notably, we found that the prevalence of CLA-resistance was 20.5%, which was higher than that from Spain (0%) ([@B12]), Netherlands (1%) ([@B29]), Brazil (3%) ([@B9]), and UK (13%) ([@B8]). Due to the satisfactory antibacterial activity and rare adverse effect, macrolides have been used as the first-choice treatment for respiratory tract infection ([@B33]). Numerous literatures have demonstrated that the misuse of macrolides is associated with emergency and increased prevalence of CLA-resistant bacteria in China ([@B30], [@B31]; [@B6]), which may also serve as a major contributor to the high prevalence of CLA-resistant *M. kansasii* isolates in China. *In vitro* susceptibility of non-tuberculous mycobacteria against CLA exhibits excellent correlation with clinical outcomes ([@B8]), the high proportion of CLA-resistant *M. kansasii* in China thus highlights the urgent need to perform *in vitro* CLA susceptibility testing before the initial treatment with regimen containing CLA.

The common *in vitro* resistance to LFX and RIF was observed from our data, indicating the inclusion of these drugs in the therapeutic regimen is controversial. However, the good activity of MOX was detected in this study, which is consistent to previous results from van Ingen et al ([@B29]). A recent study revealed that the combination of MOX and CLA is associated with attenuated CLA activity in a murine model ([@B17]). Nevertheless, MOX is an alternative antimicrobial agent for the patients infected with CLA-resistant *M. kansasii*.

Point mutations at either position 2058 or 2059 in the 23S rRNA gene have been reported to confer macrolide resistance phenotypes in NTM species ([@B16]; [@B35]). For *M. avium* complex, almost 90% of CLA-resistant isolates harbor nucleotide substitutions in the 23S rRNA gene ([@B16]). In contrast, our data revealed that more than 40% of CLA-resistant *M. kansasii* isolates had no mutation at either position 2058 or 2059 of the 23S rRNA gene. The unsatisfactory correlation between *in vitro* CLA resistance and mutations of 23S rRNA indicates that other mechanisms, such as eﬄux pump and methylation of 23S rRNA, may be involved in CLA resistance for *M. kansasii* ([@B16]; [@B4]).

*Mycobacterium kansasii* subtype I is the most frequent subtype isolated from humans in many geographic areas of the world ([@B9]). In agreement with previous reports, the subtype I is also the predominant genotype of *M. kansasii* in China, the prevalence of which is similar to that in Switzerland (68%) ([@B27]), although it is lower than that in Spain (98%) ([@B25]) and Brazil (98%) ([@B9]), and higher than that in Germany (33%) ([@B22]), Poland (40%) ([@B3]), and France (43%) ([@B2]). Hence, the distribution of subtype I exhibits geographical diversity, which may be associated with the existence of different ecosystems for these microorganisms ([@B27]). In addition, only 14.1% of *M. kansasii* isolates in this study were classified as subtype II, lower than data from previous studies ([@B2]; [@B22]). Different from Subtype I, Subtype II is considered as an opportunistic agent, which seems to be more frequently isolated from HIV-infected patients ([@B27]). Thus, the low prevalence of subtype II may be due to the low epidemic of HIV in China.

Another important finding of the current study is that *M. kansasii* subtype I is associated with CLA resistance in China. Subtype I is the most common cause responsible for human infection by *M. kansasii*, while the other subtypes are likely to be isolated from environmental samples ([@B27]). We speculate that the different drug susceptibility profiles between subtype I and other subtypes may reflect their significant difference in ecological niches. Due to more frequent exposure to antibiotic selection pressure from human, subtype I emerges the higher proportion of drug resistance to increase adaptability in hosts. Given that CLA-based drug regimens are effective options for treatment of *M. kansasii* infection, the statistical difference observed in CLA-resistance between subtype I and other subtypes is reasonable. In line to our hypothesis, we also found that subtype I was more likely to be resistant to EMB, MOX, and GAT than other subtypes. Unfortunately, because the small sample size undermines the statistical power, the difference was not statistically significant. Further study with more than 200 isolates will be required to determine the potential relationship between *M. kansasii* subtypes and drug susceptibility profiles.

There were several obvious limitations in this study. First, although chronic pulmonary disease is the most frequent clinical manifestation of NTM infection, it also causes extrapulmonary diseases, such as lymphatic, skin and soft tissue diseases ([@B10]). Considering the predominance of *M. kansasii* subtype I in the pulmonary diseases from our observations, it is important to investigate the distribution of difference subtypes in the extrapulmonary infections due to *M. kansasii*. Unfortunately, the isolates enrolled in this study were only collected from suspected pulmonary tuberculosis patients, which impedes the further analysis. Second, HIV status in patients, who are at a high risk for NTM diseases ([@B13]), was not collected. Due to the relative low prevalence of HIV in China, routine HIV examination is not performed among TB patients. On the basis of our findings, future studies will be done to validate the distribution of *M. kansasii* subtypes in these special populations, which will extend our knowledge of host preference and bacterial pathogenicity among various *M. kansasii* subtypes.

Conclusion
==========

Our data demonstrate that AMK is the most active agent against *M. kansasii in vitro*, while the high proportion of CLA resistance is noted in *M. kansasii* isolates from China. Further PRA analysis reveals that subtype I is the predominant genotype of *M. kansasii* in China. In addition, *M. kansasii* subtype I is associated with CLA resistance. Given the CLA-containing regimen frequently used in the treatment *M. kansasii*, the high proportion of CLA resistance in China highlights the urgent need to perform *in vitro* CLA susceptibility testing before the initial treatment with CLA.
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